For anyone wishing to read a very comprehensive analysis of Prima Biomed, the Southern Cross Equities did produce a very positive and informative analyst report back in May 2010 (Share price was $0.14). It gave PRR a 12 months target base price of $0.60 with the opportunistic case of $1.12. All these figures were based on CVac alone and assumed no value to HPV Vaccine and Cripto-1 Antibody or the 7% interest in Trillium Therapeutics. It also assume that trials were fully funded using convertible notes to Springtree i.e. fully diluted of 1.081b shares. Note: Based on the latest appendix 3B we currently have 768.5m listed shares and 105.3m listed options.
In the report it lists out a number of reasons to invest in PRR. I will just highlight a few point from the report.
i. Performed well in IIa results
ii. CVac able to be applied to other forms of cancer, beside Ovarian.
iii. Ovarian cancer worth $2-3b annually and will possibly replace chemotherapy and become standard of care.
iv. Emphasized the strong management in place.
However, what I like about the report was the layman's term used in describing the CVac Phase IIa trial results. 4 of the 21 late staged ovarian patient registered a positive response. This 19% response rate is phenomenon as all the patient have previously failed other therapies such that based on the SCE report anything above 10% is remarkable. In addition nearly half the patient gained some form of benefit and the response was long ranging from 27-44 weeks. And let's no forget the most important issue is safety. No safety issue was measured. Showing its is superiority to chemo and radio.
I highly recommend people to read the report to gain a better understanding of what the company is trying to accomplish in the near future.
- Forums
- ASX - By Stock
- IMM
- knowing risk and why it is mitigated
IMM
immutep limited
Add to My Watchlist
2.04%
!
24.0¢

knowing risk and why it is mitigated, page-7
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
24.0¢ |
Change
-0.005(2.04%) |
Mkt cap ! $350.4M |
Open | High | Low | Value | Volume |
24.0¢ | 24.5¢ | 24.0¢ | $225.8K | 931.6K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
15 | 288990 | 24.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
24.5¢ | 21838 | 3 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
14 | 284824 | 0.240 |
12 | 537383 | 0.235 |
15 | 613580 | 0.230 |
19 | 538700 | 0.225 |
16 | 259678 | 0.220 |
Price($) | Vol. | No. |
---|---|---|
0.245 | 21838 | 3 |
0.250 | 588816 | 10 |
0.255 | 146801 | 6 |
0.260 | 73249 | 4 |
0.265 | 478482 | 4 |
Last trade - 16.10pm 15/07/2025 (20 minute delay) ? |
Featured News
IMM (ASX) Chart |
The Watchlist
HAR
HARANGA RESOURCES LIMITED.
Peter Batten, MD
Peter Batten
MD
Previous Video
Next Video
SPONSORED BY The Market Online